IBD and infliximab: Is this the end of proactive therapeutic drug monitoring? (notice n° 498997)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 00868cam a2200169 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121081815.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bresteau, Clément |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | IBD and infliximab: Is this the end of proactive therapeutic drug monitoring? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 78 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Syversen SW, Jørgensen KK, Goll GL, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients with Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA 2021; 325 (17): 1744–54 |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Uzzan, Mathieu |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 29 | 2 | 2022-02-01 | p. 251-254 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-2-page-251?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-2-page-251?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux